Catalent Inc (CTLT) Shares Sold by California Public Employees Retirement System

Share on StockTwits

California Public Employees Retirement System trimmed its holdings in Catalent Inc (NYSE:CTLT) by 8.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 173,080 shares of the company’s stock after selling 16,400 shares during the period. California Public Employees Retirement System’s holdings in Catalent were worth $5,397,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Nordea Investment Management AB lifted its position in shares of Catalent by 36.0% in the third quarter. Nordea Investment Management AB now owns 109,694 shares of the company’s stock valued at $4,997,000 after acquiring an additional 29,008 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Catalent by 29.5% in the third quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after buying an additional 1,819,020 shares in the last quarter. First Bank & Trust lifted its position in shares of Catalent by 13.9% in the fourth quarter. First Bank & Trust now owns 4,600 shares of the company’s stock worth $143,000 after buying an additional 563 shares in the last quarter. Utah Retirement Systems lifted its position in shares of Catalent by 9.4% in the third quarter. Utah Retirement Systems now owns 26,800 shares of the company’s stock worth $1,220,000 after buying an additional 2,300 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Catalent by 234.5% in the third quarter. AQR Capital Management LLC now owns 82,106 shares of the company’s stock worth $3,740,000 after buying an additional 57,562 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

In other Catalent news, SVP Lance Miyamoto sold 43,619 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $42.49, for a total transaction of $1,853,371.31. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP William Downie sold 7,315 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $42.00, for a total value of $307,230.00. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

NYSE:CTLT opened at $41.89 on Friday. Catalent Inc has a 12 month low of $29.23 and a 12 month high of $46.43. The company has a current ratio of 2.08, a quick ratio of 1.63 and a debt-to-equity ratio of 1.36. The stock has a market capitalization of $6.09 billion, a P/E ratio of 26.35, a PEG ratio of 2.29 and a beta of 1.70.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.08. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The business had revenue of $623.00 million for the quarter, compared to the consensus estimate of $608.38 million. During the same period in the prior year, the business posted $0.45 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. On average, equities research analysts anticipate that Catalent Inc will post 1.69 EPS for the current year.

CTLT has been the topic of a number of research analyst reports. TheStreet upgraded Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, February 6th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, February 6th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Wednesday, February 20th. Morgan Stanley set a $46.00 target price on Catalent and gave the stock a “buy” rating in a research report on Monday, December 3rd. Finally, Royal Bank of Canada set a $45.00 target price on Catalent and gave the stock a “buy” rating in a research report on Friday, November 16th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $47.88.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://weekherald.com/2019/03/15/catalent-inc-ctlt-shares-sold-by-california-public-employees-retirement-system.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Read More: Municipal Bonds

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.